Mode
Text Size
Log in / Sign up
Early Phase 1 N=103 Randomized Basic Science

Leptin Infusion and Endothelial Vasomotor Response

Endothelial Dysfunction · Obesity · Vasodilation · Venous Occlusion Plethysmography

Enrolled (actual)
103
Serious AEs
0.0%
Results posted
Jul 2020
Primary outcome: Primary: Forearm Blood-flow (FBF) — 1.75; 3.1; NA; NA ml/100 mg tissue/min

Study Design & Population

Study type
Interventional
Phase
Early Phase 1
Interventions
Leptin infusion plus vasodilators in healthy men (Drug); Leptin infusion in healthy men (Drug); Vasodilators in CAD patients (Drug)
Age
Pediatric, Adult, Older Adult
Sex
All
Sponsor
Stefan Soderberg
Primary completion
Oct 2006

Outcome Measures

OutcomeResultp-value
PRIMARY
Forearm Blood-flow (FBF)
1.75; 3.1; NA; NA; 3.4; NA
SECONDARY
Release of Fibrinolytic Variables (Tissue Plasminogen Activator [tPA] and Plasminogen Activator Inhibitor-1 [PAI-1])
0.56; 0.91; NA; NA; 0.73; NA
SECONDARY
Leptin
186.2; 13.1; NA; NA; 3.4; NA
SECONDARY
Systolic Blood Pressure
140; 134; NA; NA; 136; NA
SECONDARY
Heart Rate
59; 66; NA; NA; 66; NA

Summary

Adipose tissue is an active endocrine organ producing several hormones with circulatory and metabolic effects. In 1994, the hormone leptin was discovered. The lack of this hormone explained extreme obesity in rare patients and parenteral substitution restored body weight and metabolic disturbances. It was however soon discovered that most humans had too high levels which were related to development of cardiovascular diseases and diabetes. It was hypothesised that leptin induced vessel dysfunction which could explain this association. In this study, we wanted to examine the association between leptin and vessel function by using the venous occlusion plethysmography method. We used three protocols to evaluate this association. First protocol. In ten healthy males, leptin was infused locally in the forearm and forearm blood flow (FBF) was measured. Second protocol. In ten healthy males, leptin or normal saline was infused locally in the forearm and FBF was measured. Concomitantly, four vasodilatators were infused locally in the forearm in a randomised order and the response (blood flow and fibrinolysis) was measured. Third protocol. In eighty-three patients with known coronary artery disease, three vasodilators were infused locally in the forearm in a random order and response (FBF and fibrinolysis) was measured. The response was related to endogenous leptin levels. The two first protocols were performed in Umeå, Sweden whereas the third was performed in Edinburgh, UK, all in 2006.

Eligibility Criteria

Inclusion criteria protocol 1 and 2;

  • Healthy male
  • No regular medication
  • Non-smoking
  • Abstain from alcohol for 24 hours and from food, tobacco and caffeine-containing drinks for at least 4 hours before each study visit

Inclusion criteria protocol 3;

  • Established coronary artery disease
  • Stable angina pectoris
  • Documented ≥ 50% stenosis of at least one major epicardial coronary vessel

Exclusion criteria protocol 3;

  • Coronary revascularisation within three months
  • Diabetes mellitus
  • Cardiac failure (ejection fraction 190 mmHg
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04374500). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search